News Release

SALT LAKE CITY--(BUSINESS WIRE)--Apr. 16, 2018--
Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company
with a unique, proprietary platform for the development of molecular
diagnostic testing, announced today that it will discuss the Company’s
strategic direction and recent corporate developments on Thursday, April
19, 2018 at 2:00 pm ET (1:00 pm CT) in a Lytham Partners’ Virtual
Presentation and Fireside Chat. The presentation will be available
online with interested parties able to participate by following the
webcast links below at the time of the presentation.

The presentation will consist of a brief overview of the Company by
Mr. Dwight Egan, Chairman and Chief Executive Officer of the Company,
followed by questions from the audience. The event will be moderated
by Joe Diaz, managing partner at Lytham Partners.

A replay of the presentation will be available on demand following the
conclusion of the live event.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics
company that has developed and intends to manufacture and sell reagents
used for diagnostic tests that function via the detection and/or
analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic
equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements:

This press release contains forward-looking statements.Forward-looking
statements can be identified by words such as "believes," "expects,"
"estimates," "intends," "may," "plans," "will" and similar expressions,
or the negative of these words. Such forward-looking statements are
based on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.Readers
of this press release are cautioned not to place undue reliance on any
forward-looking statements.The Company does not undertake any
obligation to update any forward-looking statement relating to matters
discussed in this press release, except as may be required by applicable
securities laws.

About Co-Diagnostics

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our molecular diagnostics development platform is marketed under the brand name Co-Dx™. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.